EPO and myelodysplastic syndrome: Erythroid response, according to the IWG criteria in these patients, was in line with other MDS subtypes, with more than 60% presenting a stable and durable response; thus, our data confirm the use of recombinant erythropoietin as the appropriate first therapeutic choice in these subjects.